Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus.

The article presents a study which examines the safety and efficacy of saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in the cardiovascular outcomes of patients with type 2 diabetes mellitus. Samples include 16,492 patients who had history of cardiovascular events were randomly assigned to administer saxagliptin or placebo. Results show that a primary end point occurred in 609 patients assigned to placebo and in 613 patients assigned to saxagliptin.